Generally speaking, INT follows a "tripartite" business model as illustrated in the following figure:
The market for CNS diseases is growing faster than what pharmaceutical products can support at the moment. Through its innovative biotechnological solutions, initially INT will provide new therapeutic agents via licensing services to enhance company revenue models through the use of the 3xTg-AD mouse model. INT has already developed a strong network of valuable contacts throughout the biopharmaceutical industry in terms of clients and resources, and is committed to providing the product support and technologically innovative direction in the CNS area that are necessary to achieve its full potential.
For more information about opportunities for licensing and collaboration with INT, please contact Shawn Mojtahedian, Ph.D. at smojtahedian@innovneurotech.com